First-in-Human Single Ascending and Multiple Dose of GLPG0778

Double-blind, Placebo-controlled, Dose-ranging Trial for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending Oral Doses, and Multiple Oral Doses of GLPG0778 in Healthy Subjects.

The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) and multiple (MD) oral doses of GLPG0778 compared to placebo (with and without food).

Also, pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0778 after single and multiple oral administration will be evaluated, and, if applicable, the maximum tolerated dose determined.

Inclusion Criteria:

• healthy male
• body mass index (BMI) between 18-30 kg/m², inclusive.

Exclusion Criteria:

• any condition that might interfere with the procedures or tests in the study
• smoking
• drug or alcohol abuse